Revenue decline - Lower Q2 revenue due mainly to prior recognition of deferred revenue from Qilu partnership in Q2 2025
Lower R&D spending - Research and development expenses fell due to workforce reduction, discontinuation of in-house research, and lower clinical trial costs
Higher admin costs - General and administrative expenses rose mainly due to higher stock compensation
Key details and analyst coverage
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$1.014 mln
$700,000 (1 Analyst)
Q2 Loss Per Share
$0.03
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for Arbutus Biopharma Corp is $5.50, about 17.8% above its August 11 closing price of $4.67
Outlook and capital returns plans
Company expects to return up to $230 mln to shareholders, possibly starting in Q3 2026
ABUS•
